Guggenheim analyst Michael Schmidt upgraded Adaptimmune to Buy from Neutral with a $5 price target.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ADAP:
Guggenheim analyst Michael Schmidt upgraded Adaptimmune to Buy from Neutral with a $5 price target.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ADAP: